Funding

PART B: VALORISATION PLAN

SECTION I: ESTIMATION OF COSTS

 

1 Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
… in terms of IPR protection
 

1000-1500 EUR for IPR protection through a utility model

2000-3000 EUR for IPR protection through patent – for the local market only.

 

 

 

 

…in terms of product development
No further product development is needed. The product is ready for industrial production.

 

 

…in terms of mass production
 

In terms of mass production it would be recommendable to organise it with a strategic partner, e.g. an enterprise from the chemical industry that already has in place some of the equipment needed to optimise investments.

In that case an amount of about 15 000 EUR is envisaged to be needed for introducing this product into the industrial site of that enterprise.

 

 

… in terms of marketing
Provided that the production is organised jointly with another industrial enterprise the marketing costs are not expected to be high as that enterprise is supposed to already have its distribution channels for the other chemical products of its portfolio. With this in mind, the costs for marketing are estimated to be about 5-7 000 EUR a year.

 

 

 

2 Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs
  Year 1 Year 2 Year 3 Year 4 Year 5
Fixed costs 10 000 EUR 20 000 40 000 40 000 40 000
Personnel 15 000 20 000 25 000 25 000 25 000
Other running costs 3 000 5 000 5 000 5 000 5 000
Marketing costs 7 000 5 000 5 000 5 000 5 000
TOTAL EXPECTED COSTS 35 000 50 000 75 000 75 000 75 000
Price per Unit 8 EUR/kg 8 EUR/kg 8 EUR/kg 8 EUR/kg 8 EUR/kg
Type of Unit kg
Number of Units 2 000 5 000 10 000 10 000 12 000
TOTAL Expected Revenues 16 000 40 000 80 000 80 000 96 000
CASH FLOW REQUIRED (REVENUES-COSTS) -19 000 -10 000 5 000 5 000 21 000
TOTAL CAPITAL required for five years  

 

 

SECTION 2: QUALITATIVE FACTORS

 

3 Dimension of identified target groups
The target market are mainly companies from the construction, transport and energy sectors. These are about 200-300 companies in total in Buglaria – potential clients.

An assumption can be made that with the exit from the present financil crisis the consumption of chemical products will gruadually grow as the sectors increase their performance ont he local market.

 

 

 

4 Evaluation of financial Risks for R&D result
As no significant investments are envisaged and the production is intended to be organised jointly with a chemical enterprise, no considerable financial risks are expected. The return of the small investments needed in putting the prduct in industrial production shall be highly dependent on the distribution channels of the strategic partner (the industrial enterprise that shall undertake the production) and the marketing.

 

 

 

 

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

 

1. European Funding

Define relevance of the product with the following potential funding sources and comment

1. Competitiveness Operational Programme – grant scheme for commercialisation of innovative products

2.

3.

4.

 

2. National Funding
1. …N/A

2.

3.

 

3. Private funding
1. …private financing from the enterprise that will be the strategic partner for industrial production.

2. …Bank loan

3.

 

4. Other

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
Provided that industrial production is organised jointly with an already operating industrial chemical enterprise, the costs for setting up the production are relatively small. Hence it is not deemed justifiable for the institute to set up a separate spin-off enterprise or a completely independent enterprise for the production of this product only.

The most appropriate way of going on the market would be to outsource the production to the strategic partner as mentioned above. This can be negotiated through aManufacturing Agreement or a Commercial Agreement with Technical Assistance. Thus the needed financing can be secured by the strategic partner, mainly with own financial resources. If the company decides to apply for funding under the Competitiveness Operational Programme, then it would have to acquire the IPR protection rights, that shall belong to the Institute, through Licensing agreement or Joint-Venture.

 

 

 

 

 

 

Decision of evaluation

  • The R&D has a high potential of exploitation
Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project